<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Several clinical studies have shown the benefits of renin-angiotensin system (<z:mp ids='MP_0011356'>RAS</z:mp>) blockade in the development of <z:mp ids='MP_0002055'>diabetes</z:mp>, and a local <z:mp ids='MP_0011356'>RAS</z:mp> has been identified in pancreatic islets </plain></SENT>
<SENT sid="1" pm="."><plain>Angiotensin I-converting enzyme (ACE)2, a new component of the <z:mp ids='MP_0011356'>RAS</z:mp>, has been identified in the pancreas, but its role in β-cell function remains unknown </plain></SENT>
<SENT sid="2" pm="."><plain>Using 8- and 16-week-old <z:mp ids='MP_0001261'>obese</z:mp> db/db mice, we examined the ability of ACE2 to alter pancreatic β-cell function and thereby modulate <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: Both db/db and nondiabetic lean control (db/m) mice were infected with an adenovirus expressing human ACE2 (Ad-hACE2-eGFP) or the control virus (Ad-eGFP) via injection into the pancreas </plain></SENT>
<SENT sid="4" pm="."><plain>Glycemia and β-cell function were assessed 1 week later at the peak of <z:mp ids='MP_0001799'>viral</z:mp> expression </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In 8-week-old db/db mice, Ad-hACE2-eGFP significantly improved fasting glycemia, enhanced intraperitoneal <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance, increased islet insulin content and β-cell proliferation, and reduced β-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> compared with Ad-eGFP </plain></SENT>
<SENT sid="6" pm="."><plain>ACE2 overexpression had no effect on insulin sensitivity in comparison with Ad-eGFP treatment in diabetic mice </plain></SENT>
<SENT sid="7" pm="."><plain>Angiotensin-(1-7) receptor blockade by<z:chebi fb="2" ids="29949"> D-Ala</z:chebi>(7)-Ang-(1-7) prevented the ACE2-mediated improvements in intraperitoneal <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance, glycemia, and islet function and also impaired insulin sensitivity in both Ad-hACE2-eGFP- and Ad-eGFP-treated db/db mice </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="32437">D-Ala</z:chebi>(7)-Ang-(1-7) had no effect on db/m mice </plain></SENT>
<SENT sid="9" pm="."><plain>In 16-week-old diabetic mice, Ad-hACE2-eGFP treatment improved fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> but had no effect on any of the other parameters </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: These findings identify ACE2 as a novel target for the prevention of β-cell dysfunction and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> occurring in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>